Alterity ATHE: Megapotential durch geringe Bewertung und attraktiver Pipeline

[Blitzableiter]

Am Wochenende und in zwei Wochen werden neue Daten gemeldet. Ein aEinstieg könnte sich lohnen!

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.

Title:
Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Friedreich’s Ataxia
Lead Author:
Ashley Pall, Department of Pharmaceutical Sciences, Wayne State University


As previously announced, three posters from the Company’s development pipeline will also be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.

Title:
A Phase 2 Study of ATH434, a Novel Inhibitor of α-Synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA)
Lead Author:
David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics
Date/Time:
Sunday, April 14, from 11:45 a.m. to 12:45 p.m. Mountain Time (U.S.)


Title:
Neurofilament Light Chain and Clinical Progression in Early Multiple System Atrophy
Lead Author:
Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center
Date/Time:
Monday, April 15, from 5:30 p.m. to 6:30 p.m. Mountain Time (U.S.)


Title:
Effects of ATH434, a Clinical-phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques
Lead Author:
Margaret Bradbury, Vice President, Research and Nonclinical Development, Alterity Therapeutics
Date/Time:
Tuesday, April 16, from 11:45 a.m. to 12:45 p.m. Mountain Time (U.S.)


About ATH434

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission.